Information
Address

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Switchboard:

Switchboard

+33 (0)1 42 11 42 11

GUSTAVE ROUSSY
1st cancer center in Europe

© 2006-2015 Gustave Roussy – All rights reserved

Fundamental genomics platform - Publications

back to job offer list
back to clinical trials

Main publications

DNA polymerase zeta contributes to heterochromatin replication to prevent genome instability. Ben Yamin B, Ahmed-Seghir S, Tomida J, Despras E, Pouvelle C, Yurchenko A, Goulas J, Corre R, Delacour Q, Droin N, Dessen P, Goidin D, Lange SS, Bhetawal S, Mitjavila-Garcia MT, Baldacci G, Nikolaev S, Cadoret JC, Wood RD, Kannouche PL. EMBO J. 2021 Sep 17:e104543. doi: 10.15252/embj.2020104543. Online ahead of print. PMID: 34533226

Témoignage - Odile

back to job offer list
back to clinical trials

Ils nous soutiennent

Odile
Testatrice de Gustave Roussy

2022
01/03/2022

Meilleurs vœux pour l’année 2022

Toutes les équipes de Gustave Roussy vous présentent leurs meilleurs vœux pour l’année 2022 !

Type of cancer

back to job offer list
back to clinical trials

Type of cancer

Programme Interval - Risk Prediction of Severe Cancer-Related Fatigue in Survivors of Breast Cancer

back to job offer list
back to clinical trials

 

Risk Prediction of Severe Cancer-Related Fatigue in Survivors of Breast Cancer

This prediction tool calculates the estimated probability of reporting Severe Cancer-Related Fatigue in Survivors of Breast Cancer at 2 years and 4 years after diagnosis based on patient characteristics.

► Access to the prediction tool

 

 

Quatre projets majeurs de Gustave Roussy seront financés par le Programme d’Investissements d’Avenir

back to job offer list
back to clinical trials

Villejuif, le 15 décembre 2021

Quatre projets majeurs de Gustave Roussy seront financés par le Programme d’Investissements d’Avenir

Parmi les 17 projets de recherche innovants et de grande ampleur dans le domaine de la santé retenus dans le cadre du 5e appel à projets de l’action "Recherche hospitalo-universitaire en santé" (RHU) du Programme Investissements d’Avenir, figurent quatre projets coordonnés par Gustave Roussy :

Pharmacovigilance Unit - The REISAMIC registry

back to job offer list
back to clinical trials

The REISAMIC registry

Registry of Severe Adverse Reactions to Immunomodulatory Monoclonal Antibodies used in Oncology (REISAMIC)
 

Pharmacovigilance Unit - The PREMIS Study

back to job offer list
back to clinical trials

The PREMIS Study

In oncology, immunostimulatory agents, in particular immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA4, have revolutionised the treatment of a number of cancers. The number of patients treated with these compounds has increased considerably with the approval of numerous new drugs and the setting up of various clinical trials, notably involving associations, in different indications.
 

Pages